DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer Written by PR Newswire Enable JavaScript and cookies to continueRead more http://www.prnasia.com/story/archive/4930631_CN30631_0